Medifast, Inc.

Medifast, Inc.

MEDยทNYSE

$12.24

-0.61%
Consumer CyclicalPersonal Products & Services

Medifast, Inc., through its subsidiaries, manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutritional products in the United States and the Asia-Pacific. The company offers bars, bites, pretzels, puffs, cereal crunch, drinks, hearty choices, oatmeal, pancakes, pudding, soft serves, shakes, smoothies, soft bakes, and soups under the OPTAVIA, Optimal Health by Take Shape for Life, and Flavors of Home brands. It markets its products through point-of-sale transactions over ecommerce platform. The company was founded in 1980 and is headquartered in Baltimore, Maryland.

At a Glance

Live Snapshot
Market Cap$136.10M
EPS-1.7000
P/E Ratio-7.20
Earnings Date08/03/2026

Intrinsic Alpha Methodology

Thesis Lenses

Signal ยท Driver ยท Risk

Signal

Medium confidence

Valuation multiple is compressed (P/E -7.2).

Valuation inputs: P/E -7.2, earnings yield N/A, momentum -0.6%.

If multiples stay elevated while momentum fades, downside repricing risk rises.

Driver

High confidence

Return profile is soft (ROE -9.4%, ROIC -6.5%).

Profitability stack: net margin -4.8%, ROE -9.4%, ROIC -6.5%.

Quality deterioration often appears in margins before it shows up in headline EPS.

Risk

High confidence

Risk profile is balanced but has notable pressure points to monitor.

Risk factors: liabilities/assets +22.6%, momentum -0.6%, net margin -4.8%.

Higher leverage with weak momentum and thin margins can amplify drawdown severity.

med

Medifast, Inc. Market vs Earnings Trajectory

MED ยท NYSE

Loading price and EPS data...

Medifast, Inc.

Medifast, Inc. Fair Value Envelope

MED ยท NYSE

Our analysis suggests that MED has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $12.24, this represents a potential HIDDEN relative to our calculated worth for Medifast, Inc..

Intrinsic Value
Current Price: $12.24
3Y-113.0%
5Y-119.0%
10Y-213.0%
3Y-76.0%
5Y-59.0%
10Y+41.0%
3Y-113.0%
5Y-118.0%
10Y-205.0%
3Y-96.0%
5Y-95.0%
10Y-73.0%
3Y-99.0%
5Y-99.0%
10Y-94.0%
3Y-19.0%
5Y-7.0%
10Y+112.0%
Medifast, Inc.

Medifast, Inc. Profit Bridge

MED ยท NYSE
Revenue385.79M
Cost of Goods Sold (110.60M)
Gross Profit275.19M
Operating Expenses (289.40M)
Operating Income-14.21M
Interest Expense (0.00)
Other Income/Expense8.57M
Pretax Income-5.64M
Income Tax (13.03M)
Net Income-18.67M
Net Income
-18.67M

Profitability Analysis

Gross Margin

71.3%

Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.

Operating Margin

-3.7%

Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.

Net Profit Margin

-4.8%

Net losses indicate the company is burning cash. Sustainability depends on path to profitability.

Profitability Insight

Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.

71.33%
Gross Profit Margin
-3%
3Y-
5Y-4.0%
10Y-5.0%
-3.68%
Operating Profit Margin
-871%
3Y-132.0%
5Y-126.0%
10Y-138.0%
-4.84%
Net Profit Margin
-1494%
3Y-154.0%
5Y-144.0%
10Y-175.0%
-9.39%
Return on Equity
-1043%
3Y-110.0%
5Y-114.0%
10Y-151.0%
-7.27%
Return on Assets
-1087%
3Y-116.0%
5Y-120.0%
10Y-149.0%
-6.50%
Return on Invested Capital
-1025%
3Y-108.0%
5Y-111.0%
10Y-136.0%
MED

Medifast, Inc. Cash Conversion Engine

MED ยท NYSE
Net Income-18.67M
Depreciation & Amortization14.24M
Stock-Based Compensation7.64M
Change in Working Capital-9.80M
Others2.00M
Capital Expenditures-5.61M
Free Cash Flow1.25M

Cash Flow Quality Analysis

FCF Conversion Rate

-6.7%

Negative free cash flow despite positive earnings raises concerns about cash generation ability or heavy capital requirements.

CapEx Intensity

81.8%

Very high capital intensity consumes most operating cash flow. Limited flexibility for dividends or debt reduction.

FCF Growth Trend

-92.7%

Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.

Working Capital Impact

-$9.80M

Significant working capital drain. Growth may be consuming cash through inventory buildup or receivables extensionโ€”monitor closely.

Cash Flow Quality Insight

Deteriorating cash generation: Both declining FCF and weak conversion rate signal fundamental challenges. Investigate margin pressure, rising costs, or working capital issues.

med

Medifast, Inc. Funding & Solvency Profile

MED ยท NYSE
Cash & Cash Equivalents71.53M
Net Receivables0.00
Inventory21.40M
Other Current Assets109.70M
Total Current Assets203 M
Property, Plant & Equipment42.56M
Goodwill & Intangible Assets0.00
Long-Term Investments0.00
Other Non-Current Assets6.85M
Total Non-Current Assets49 M
Total Assets
252.05M

Financial Health Analysis

Current Ratio

4.80x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.28x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

160 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

80% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

med

Medifast, Inc. Street Expectations Map

MED ยท NYSE

Wall Street analysts project that MED stock may see slight declines over the coming 12 months. The consensus 1-year price target stands at 12.00, with estimates ranging from a low of 12.00 to a high of 12.00.

Lowest Target
12.00
-1.96%
Consensus Target
12.00
-1.96%
Highest Target
12.00
-1.96%

The consensus 1-year price target stands at 12.00, with estimates ranging from a low of 12.00 to a high of 12.00.

Analyst Consensus Analysis

Upside Potential

-2.0%

Fair value territory. Stock trading near consensus target suggests limited near-term catalysts. Focus on fundamental developments.

Analyst Agreement

0.0% spread

High analyst agreement. Narrow target range indicates strong consensus on valuation, suggesting clear investment thesis and predictable outlook.

Risk-Reward Profile

1.00x

Balanced risk-reward. Upside and downside potential relatively symmetric. Suitable for moderate risk tolerance with conviction in thesis.

Analyst Conviction

Moderate

Neutral sentiment. Fair value pricing with moderate agreement suggests wait-and-see approach or catalyst-driven opportunity.

Market Sentiment Insight

Efficient pricing: Stock trading at fair value with strong consensus suggests market has priced in expectations. Look for fundamental inflection points or new catalysts to drive meaningful moves.

med

Medifast, Inc. Insider Positioning

MED ยท NYSE

During the last 12 months, insiders have purchased $247K worth of MED shares, with no selling activity reported.

3 Months

Bought

22.7K

241.67K

Sold

0

0.00

Net Activity

+242K

+$242K

3-6 Months

Bought

0

0.00

Sold

0

0.00

Net Activity

+0

+$0

6-9 Months

Bought

0

0.00

Sold

0

0.00

Net Activity

+0

+$0

9-12 Months

Bought

381

5.00K

Sold

0

0.00

Net Activity

+5K

+$5K

Top Buyers

1
CDR

Chard Daniel R

Director, Officer: Chairman & Ceo

18.1K sharesโ€ข2 transactions

$184K

2
SS

Schlackman Scott

Director

5.0K sharesโ€ข2 transactions

$63K

Top Sellers

No selling activity

Insider Activity Analysis

Net Insider Sentiment

Bullish

Strong bullish signal with $247K net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.

Buy/Sell Ratio

โˆž:1

Perfect buy/sell ratio. Only buying activity with zero sellingโ€”the most bullish possible insider signal.

Recent Trend (3 Months)

$242K

Very strong recent buying momentum. Recent insider purchases significantly outpace sales, suggesting near-term optimism.

Insider Participation

High Buying

2 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.

Insider Activity Insight

Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.

0.00%
Dividend Yield
3Y-100.0%
5Y-100.0%
10Y-100.0%
ย 

med Dividend History

MED
10Y CAGR +21%
Latest $1.65
Annual $8.23
5 year growth trend
Last Period: +0%